CN104367908B - It is a kind of to treat pharmaceutical composition of angiocardiopathy and its production and use - Google Patents
It is a kind of to treat pharmaceutical composition of angiocardiopathy and its production and use Download PDFInfo
- Publication number
- CN104367908B CN104367908B CN201410339490.8A CN201410339490A CN104367908B CN 104367908 B CN104367908 B CN 104367908B CN 201410339490 A CN201410339490 A CN 201410339490A CN 104367908 B CN104367908 B CN 104367908B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- powder
- ultramicro
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of pharmaceutical composition for treating angiocardiopathy, it is the preparation being prepared from by the Ultramicro-powder of following weight proportion bulk drug：230.4 parts of the red sage root, 25.6 parts of santal, 51.2 parts of dalbergia wood, 38.4 parts of kaempferia galamga, 76.8 parts of nutmeg, 76.8 parts of fructus choerospondiatis, 76.8 parts of sea-buckthorn.Present invention research shows, during by the Ultramicro-powder of the taste prescription material ultramicro grinding of coronary disease seven to 10~80 μm, can preferably retain the active ingredient in medicinal material, significantly increase drug activity, wherein especially the most notable with 20 μm of Ultramicro-powders activity.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for treating angiocardiopathy and its production and use.
Background technology
The taste side of coronary disease seven, the side being made up of the red sage root, santal, dalbergia wood, kaempferia galamga, nutmeg, fructus choerospondiatis, sea-buckthorn seven flavor medicine material
Agent, promoting blood circulation and removing blood stasis, cardiac stimulant is relieved pain, for coronary heart disease, vexed palpitaition, angina pectoris.
The extraction of medicinal material is carried out more than the current prescription using the double formulations of alcohol water, to guarantee in medicinal material effectively
Fat-soluble and water soluble ingredient is extracted, so as to improve the utilization rate of medicinal material and ensure good drug activity.
As the extraction process of the taste dripping pill of coronary disease seven is：The taste of the above seven, how ﹑ nutmegs extract volatile oil on Tan Xiang ﹑ drop perfume ﹑ mountains,
The another device of the aqueous solution after distillation is collected；The three taste medicinal materials such as the dregs of a decoction and remaining red sage root extract secondary with 95% ethanol, 1 hour every time,
Filtration, the dregs of a decoction add water to cook secondary, and 1.5 hours every time, filtration concentrated each extract solution to thick paste respectively, merges each concentrate, subtracts
Press dry dry, be ground into fine powder, obtain extract powder, add volatile oil and be mixed and made into 1000 balls with PEG, produce.
The extraction process of coronary disease tablet of seven ingredients is：The taste of the above seven, santal, dalbergia wood, kaempferia galamga, the taste co-grinding of nutmeg four are into thin
Powder, three tastes such as remaining red sage root are extracted three times, for the first time plus alcohol reflux is extracted 2 hours, and it is small that second plus 70% ethanol extract 2
When, filtrate merges, filtration, reclaims ethanol and obtains thick shape ointment, add water to cook for the third time 2 hours, filter, filtrate is condensed into thick paste,
Two cream merge, and the fine powders such as santal are merged with thick paste, low temperature drying, are ground into fine powder, pelletize, and dry, and are pressed into 1000, bag
Sugar-coat, is produced.
The content of the invention
The present invention relates to a kind of pharmaceutical composition for treating angiocardiopathy and its production and use.
The invention provides a kind of pharmaceutical composition for treating angiocardiopathy, it is by following weight proportion bulk drug
The preparation that Ultramicro-powder is prepared from：
230.4 parts of the red sage root, 25.6 parts of santal, 51.2 parts of dalbergia wood, 38.4 parts of kaempferia galamga, 76.8 parts of nutmeg, 76.8 parts of fructus choerospondiatis,
76.8 parts of sea-buckthorn；Wherein, the particle diameter of the Ultramicro-powder is 10~80 μm.
Preferably, the particle diameter of the Ultramicro-powder is 20 μm.
Wherein, the preparation is oral formulations.
Further, the oral formulations are tablet, capsule, pill, powder, granule.
Present invention also offers the preparation method of aforementioned pharmaceutical compositions, it includes following operating procedure：
(1) bulk drug is weighed by weight ratio：
(2) each bulk drug is taken, uses superfine communication technique preparation to be crushed to particle diameter for 10~80 μm of Ultramicro-powder, adds
Pharmaceutically conventional auxiliary material or complementary composition are prepared into preparation.
Further, the particle diameter of the Ultramicro-powder is 20 μm.
Present invention also offers purposes of the aforementioned pharmaceutical compositions in the medicine for preparing treatment myocardial ischemia.
Present invention also offers purposes of the aforementioned pharmaceutical compositions in the medicine for preparing treatment coronary heart disease.
Present invention research shows, can be preferably during by the Ultramicro-powder of the taste prescription material ultramicro grinding of coronary disease seven to 10~80 μm
Retain the active ingredient in medicinal material, significantly increase drug activity, wherein especially the most notable with 20 μm of Ultramicro-powder activity.
Embodiment
The preparation of the capsule of embodiment 1
【Prescription】Raw material：Red sage root 230.4g santal 25.6g dalbergia woods 51.2g
Kaempferia galamga 38.4g nutmeg 76.8g fructus choerospondiatis 76.8g
Sea-buckthorn 76.8g
Auxiliary material：Microcrystalline cellulose 150g lactose 75g
1000 capsules are made
The taste of the above seven, uses superfine communication technique to mix or be individually ground into particle diameter for 20 μm of medicinal powder, at addition
The microcrystalline cellulose and lactose of side's amount are mixed, plus appropriate Diluted Alcohol, mixed with above powder, particle is made, dried, encapsulated,
Produce.
The preparation of the tablet of embodiment 2
【Prescription】Raw material：Red sage root 230.4g santal 25.6g dalbergia woods 51.2g
Kaempferia galamga 38.4g nutmeg 76.8g fructus choerospondiatis 76.8g
Sea-buckthorn 76.8g
Auxiliary material：Starch 150g dextrin 75g talcum powder 50g
1000 are made altogether
The taste of the above seven, uses superfine communication technique to mix or be individually ground into particle diameter for 20 μm of medicinal powder, at addition
The starch and dextrin of side's amount are mixed, plus appropriate Diluted Alcohol, mixed with above powder, particle is made, dried, and are added after talcum powder and are mixed
Even, tabletting, sugar coating is produced.
The preparation of the soft capsule of embodiment 3
【Prescription】Raw material：Red sage root 115.2g santal 12.8g dalbergia woods 25.6g
Kaempferia galamga 19.2g nutmeg 38.4g fructus choerospondiatis 38.4g
Sea-buckthorn 38.4g
Auxiliary material：Soybean oil 300g
1000 soft capsules are made
The taste of the above seven, uses superfine communication technique to mix or be individually ground into particle diameter for 20 μm of medicinal powder, adds big
Soya-bean oil, mixes, is pressed into soft capsule, produces.
The drug effect contrasts of the taste sample of coronary disease seven prepared by the different process of embodiment 4
1 experimental animal
KM mouse, SPF grades, ♀/♂ half and half, 18.5~22.5g of body weight are provided by Chengdu up to large bio tech ltd,
Quality of Experimental Animals quality certification number：scxkc(111)2008-24.
2 Experimental agents
Red sage root 230.4g, santal 25.6g, dalbergia wood 51.2g, kaempferia galamga 38.4g, nutmeg 76.8g, fructus choerospondiatis 76.8g, sea-buckthorn
76.8g。
Sample one：Santal, dalbergia wood, kaempferia galamga, nutmeg four traditional Chinese medicine thing co-grinding are taken into fine powder, the three taste medicines such as remaining red sage root
Thing is extracted three times, adds alcohol reflux to extract 2 hours for the first time, and the ethanol for Jia 70% for the second time is extracted 2 hours, and filtrate merges, and is filtered
Cross, reclaim ethanol and obtain paste thing, add water to cook for the third time 2 times, filter, filtrate is condensed into thick paste, and two cream merge, by santal etc.
Fine powder is mixed thoroughly with thick paste, low temperature drying, is ground into fine powder, granulation, is drying to obtain.
Sample two：The taste medicinal material of recipe quantity red sage root etc. 7 is taken, is about into particle diameter by 7 taste pulverizing medicinal materials using superfine communication technique
10 μm of Ultramicro-powder.
Sample three：The taste medicinal material of recipe quantity red sage root etc. 7 is taken, is about into particle diameter by 7 taste pulverizing medicinal materials using superfine communication technique
20 μm of Ultramicro-powder.
Sample four：The taste medicinal material of recipe quantity red sage root etc. 7 is taken, is about into particle diameter by 7 taste pulverizing medicinal materials using superfine communication technique
40 μm of Ultramicro-powder.
Sample five：The taste medicinal material of recipe quantity red sage root etc. 7 is taken, is about into particle diameter by 7 taste pulverizing medicinal materials using superfine communication technique
80 μm of Ultramicro-powder.
Sample six：The taste of the above seven, how ﹑ nutmegs extract volatile oil on Tan Xiang ﹑ drop perfume ﹑ mountains, and the another device of the aqueous solution after distillation is received
Collection；The three taste medicinal materials such as the dregs of a decoction and remaining red sage root extract secondary with 95% ethanol, 1 hour every time, and filtration, the dregs of a decoction add water to cook two
Secondary, 1.5 hours every time, filtration concentrated each extract solution to thick paste, merges each concentrate, be dried under reduced pressure, be ground into fine powder respectively,
Obtain extract powder.
3 kits
(1) Mice ATP Elisa kits.
(2) Mice CPK Elisa kits.
(3) Mice LDH Elisa kits.
4 statistical methods
Statistical analysis is carried out with SPSS17.0 softwares.Data with mean ± standard deviation () represent, Dan Yin is used between group
LSD inspections are carried out between plain variance analysis, the neat person's group of variance, heterogeneity of variance person carries out Tamhane ' s T2 and examined.
5 experiment contents and method
5.1 experiment packets and administration
KM mouse are randomly divided into 9 groups by body weight, every group 10, respectively as：1. model control group：Isometric pure water；
2. one group of sample：2.4g·kg-1；3. two groups of sample：2.4g·kg-1；4. three groups of sample：2.4g·kg-1；5. four groups of sample：
2.4g·kg-1；6. five groups of sample：2.4g·kg-1；7. six groups of sample：2.4g·kg-1；8. positive group (the taste dripping pill of coronary disease seven
Group)：2.4g·kg-1.It is another to weigh 10 normal mouses at random by body weight as Normal group 9.：Isometric pure water.Every group
The daily gavage of mouse 1 time, continuous 10d.Chinese medicine group is with crude drug gauge.
5.2 mouse cardiac muscle ischemia model clone methods
Test 9d to start, in addition to blank group, isoprel is injected intraperitoneally by 3mg/kg dosage in remaining each group mouse,
Continuous two days.Isodose physiological saline is given in naive mice intraperitoneal injection.
5.3 Testing index
1. myocardial metabolism index determining：Mouse heart donor source blood, 4000rmin-110min is centrifuged, supernatant is collected
Liquid, Elisa methods determine ATP (atriphos), CPK (creatine phosphokinase) and LDH (lactic dehydrogenase) content in blood plasma.
2. myocardial ischemia and infarction size：Each experimental mice heart is taken, it is fixed after ice normal saline flushing bloodstain
In 10% neutral formalin, paraffin is fixed, tissue dewatering, embedded section, HE dyeing, micro- each experimental mice heart of sem observation
Myocardial ischemia infarction size.
5.4 experimental result
5.4.1 the influence to mice plasma ATP contents the results are shown in Table 2.
ATP contents in each experimental mice blood plasma of table 2 (N=10)
Note：Compared with model group：**P<0.01；*P<0.05；One group is compared with sample：△△P<0.01,△P<0.05；With sun
Property group compares：▲▲P<0.01,▲P<0.05。
As shown in Table 2, compared with blank group, model group mice plasma ATP contents have pole to significantly reduce (P<0.01)；With mould
Type group compares, positive group, one group of sample, two groups, four groups, five groups, six groups of mice plasma ATP contents have significantly rise (P<
0.05), three groups of sample has extremely notable rise (P<0.01)；One group is compared with sample, the group mice plasma ATP contents of sample two to six
There is significantly rise (P<0.05)；Compared with positive group, three groups of mice plasma ATP contents of sample have significantly rise (P<0.05).
5.4.2 the influence to mice plasma CPK contents the results are shown in Table 3.
CPK contents in each experimental mice blood plasma of table 3 (N=10)
Note：Compared with model group：**P<0.01；*P<0.05；One group is compared with sample：△△P<0.01,△P<0.05；With sun
Property group compares：▲▲P<0.01,▲P<0.05。
As shown in Table 3, compared with blank group, model group mice plasma CPK contents have extremely notable rise (P<0.01)；With mould
Type group compares, one group of sample, two groups, four groups, five groups, six groups of mice plasma CPK contents significantly reduce (P<0.05), sample
Three groups have pole to significantly reduce (P<0.01)；One group is compared with sample, two groups of sample, four groups, five groups, six groups of mice plasma CPK contain
Amount significantly reduces (P<0.05), three groups of sample has pole to significantly reduce (P<0.01)；Compared with positive group, three groups of mouse of sample
Plasma C PK contents significantly reduce (P<0.05).
5.4.3 the influence to mice plasma LDH contents the results are shown in Table 4.
LDH contents in each experimental mice blood plasma of table 4 (N=10)
Note：Compared with model group：**P<0.01；*P<0.05；One group is compared with sample：△△P<0.01,△P<0.05；With sun
Property group compares：▲▲P<0.01,▲P<0.05。
As shown in Table 4, compared with blank group, model group mice plasma LDH contents have extremely notable rise (P<0.01)；With mould
Type group compares, and the group mice plasma CPK contents of sample two to six have pole to significantly reduce (P<0.01)；One group is compared with sample, sample
Two groups of product, four groups, five groups, six groups of mice plasma LDH contents significantly reduce (P<0.05), three groups of sample has pole to significantly reduce
(P<0.01)；Compared with positive group, three groups of mice plasma LDH contents of sample significantly reduce (P<0.05).
5.4.4 the influence to mouse cardiac muscle ischemic infarction area the results are shown in Table 5.
Each experimental mice myocardial tissue damage index of table 5 (N=10)
Note：Compared with model group：**P<0.01；*P<0.05；One group is compared with sample：△△P<0.01,△P<0.05；With sun
Property group compares：▲▲P<0.01, ▲ P<0.05.
As shown in Table 5, compared with blank group, model group murine myocardial infarction area significantly increases (P<0.05)；With mould
Type group compares, and the group murine myocardial infarction area of sample two to six is substantially reduced (P<0.05)；One group is compared with sample, sample
Two groups, four groups, five groups, six groups of murine myocardial infarction areas be substantially reduced (P<0.05), three groups of sample has pole to be substantially reduced
(P<0.01)；Compared with positive group, three groups of murine myocardial infarction areas of sample are substantially reduced (P<0.05).
6 experiment conclusions
The taste side of coronary disease seven is directly prepared into powder using superfine communication technique and taken than using coronary disease tablet of seven ingredients preparation technology tool
There is more curative effect, its ultra micro particle size range is：10 μm~80 μm, wherein, the optimal medicinal powder particle diameter of drug effect is 20 μm.
Claims (6)
1. a kind of pharmaceutical composition for treating angiocardiopathy, it is characterised in that：It is by the super of following weight proportion bulk drug
The preparation that micro mist is prepared from：
230.4 parts of the red sage root, 25.6 parts of santal, 51.2 parts of dalbergia wood, 38.4 parts of kaempferia galamga, 76.8 parts of nutmeg, 76.8 parts of fructus choerospondiatis, sea-buckthorn
76.8 parts；The particle diameter of the Ultramicro-powder is 20 μm.
2. pharmaceutical composition according to claim 1, it is characterised in that：The preparation is oral formulations.
3. pharmaceutical composition according to claim 2, it is characterised in that：The oral formulations are tablet, capsule, ball
Agent, powder, granule.
4. the preparation method of claims 1 to 3 any one described pharmaceutical composition, it is characterised in that：It includes following operation
Step：
(1) bulk drug is weighed by weight ratio：
(2) each bulk drug is taken, uses superfine communication technique preparation to be crushed to particle diameter for 20 μm of Ultramicro-powder, along with pharmaceutically normal
Auxiliary material or complementary composition are prepared into preparation.
5. purposes of the claims 1 to 3 any one described pharmaceutical composition in the medicine for preparing treatment myocardial ischemia.
6. purposes of the claims 1 to 3 any one described pharmaceutical composition in the medicine for preparing treatment coronary heart disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410339490.8A CN104367908B (en) | 2013-08-12 | 2014-07-16 | It is a kind of to treat pharmaceutical composition of angiocardiopathy and its production and use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310349159 | 2013-08-12 | ||
| CN201310349159X | 2013-08-12 | ||
| CN201410339490.8A CN104367908B (en) | 2013-08-12 | 2014-07-16 | It is a kind of to treat pharmaceutical composition of angiocardiopathy and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104367908A CN104367908A (en) | 2015-02-25 |
| CN104367908B true CN104367908B (en) | 2017-09-15 |
Family
ID=52547268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410339490.8A Active CN104367908B (en) | 2013-08-12 | 2014-07-16 | It is a kind of to treat pharmaceutical composition of angiocardiopathy and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367908B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018090380A1 (en) * | 2016-11-21 | 2018-05-24 | 内蒙古天奇中蒙制药股份有限公司 | Capsule and preparation process therefor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839905A (en) * | 2005-03-30 | 2006-10-04 | 海口绿科南药研究开发有限公司 | Supermicropowder soft capsule formulation and preparation method thereof |
| CN1846722A (en) * | 2006-02-21 | 2006-10-18 | 修涞贵 | Superfine Chinese medicine powder prepn for treating cardiovascular diseases and its prepn process |
-
2014
- 2014-07-16 CN CN201410339490.8A patent/CN104367908B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839905A (en) * | 2005-03-30 | 2006-10-04 | 海口绿科南药研究开发有限公司 | Supermicropowder soft capsule formulation and preparation method thereof |
| CN1846722A (en) * | 2006-02-21 | 2006-10-18 | 修涞贵 | Superfine Chinese medicine powder prepn for treating cardiovascular diseases and its prepn process |
Non-Patent Citations (2)
| Title |
|---|
| 中药超微粉碎技术的研究进展;邓雯等;《食品与药品》;20071231;第9卷(第11A期);第59-62页 * |
| 蒙药冠心活血散治疗冠心病心绞痛60例临床观察;张丽华等;《中国民族民间医药》;20130228;第7页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104367908A (en) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| CN102145060B (en) | Application of traditional Chinese medicine composition in the drugs of the preparation of the coronary heart disease with inquietude and depression | |
| CN100502833C (en) | Novel preparing method for Tibetan medicine Qingpeng ointment | |
| CN1814170B (en) | Medicinal drop pills for treating cardiovascular disease and preparing method | |
| CN100353968C (en) | Chinese medicine preparation for nourishing blood and tranquilizing mind and its preparation process | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| CN104367908B (en) | It is a kind of to treat pharmaceutical composition of angiocardiopathy and its production and use | |
| CN104069144A (en) | Three formula granules for forming Shengmai powder and preparation method thereof | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN102600231A (en) | Anti-fatigue nutrient and preparation method thereof | |
| CN105726921A (en) | Traditional Chinese medicine composition and preparation for treating deficiency of both qi and blood | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN100387250C (en) | Dripping pills of corydalis tuber and its preparation process | |
| CN102283920B (en) | Medicinal composition for treating parkinson disease as well as preparation method and application thereof | |
| CN111228419A (en) | Mailuoshutong micro pill preparation and its preparing method | |
| CN113521131B (en) | Traditional Chinese medicine composition for ischemic cardiomyopathy and application thereof | |
| CN107951951B (en) | Traditional Chinese medicine composition for removing senile plaques and preparation method thereof | |
| CN100348172C (en) | Notoginseng floral leaf drop pill in use for cleaning away heat and its prepn. process | |
| CN1326542C (en) | Bone-recovering guttate pills | |
| CN1242801C (en) | Medicinal composition for treating coronary heart disease and angine pectoris | |
| CN1724054A (en) | Medicinal prepn. for treating hypermenorrhea, and its prepn. method | |
| CN100488522C (en) | Application of epimeddium for preparing weight-reducing healthy product and medicinal preparation | |
| CN102475781B (en) | Method for preparing traditional Chinese medicine composition used for treating essential hypertension | |
| CN106389820A (en) | Extraction method for Tianwang buxin dan prescription and Shengmaiyin prescription | |
| CN114306485A (en) | Composition and medicine for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190409 Address after: 110 000 No. 12 Central Avenue, Dongdaying Industrial Park, Shenyang City, Liaoning Province Patentee after: Shenyang Kangda Pharmaceutical Group Co., Ltd. Address before: Room 206, Building 5, Gaopeng Avenue, Chengdu High-tech Zone, Sichuan 610041 Patentee before: Chengdu Baicao Heji Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 110 000 No. 12 Central Avenue, Dongdaying Industrial Park, Shenyang City, Liaoning Province Patentee after: Shenyang Qinggong Pharmaceutical Group Co., Ltd. Address before: 110 000 No. 12 Central Avenue, Dongdaying Industrial Park, Shenyang City, Liaoning Province Patentee before: Shenyang Kangda Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |